Key references: Stepwise therapy for wheeze and asthma: children 1 to 5 years
Bisgaard H, Zielen S, Garcia-Garcia ML, Johnston SL, Gilles L, Menten J, et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med 2005;171(4):315–22. https://www.ncbi.nlm.nih.gov/pubmed/15542792
Brodlie M, Gupta A, Rodriguez-Martinez CE, Castro-Rodriguez JA, Ducharme FM, McKean MC. Leukotriene receptor antagonists as maintenance and intermittent therapy for episodic viral wheeze in children. Cochrane Database Syst Rev 2015;(10):CD008202. https://www.ncbi.nlm.nih.gov/pubmed/26482324
Castro-Rodriguez JA, Rodriguez-Martinez CE, Ducharme FM. Daily inhaled corticosteroids or montelukast for preschoolers with asthma or recurrent wheezing: a systematic review. Pediatr Pulmonol 2018;53(12):1670–7. https://www.ncbi.nlm.nih.gov/pubmed/30394700
Fitzpatrick AM, Jackson DJ, Mauger DT, Boehmer SJ, Phipatanakul W, Sheehan WJ, et al. Individualized therapy for persistent asthma in young children. J Allergy Clin Immunol 2016;138(6):1608-18 e12. https://www.ncbi.nlm.nih.gov/pubmed/27777180
Fogel RB, Rosario N, Aristizabal G, Loeys T, Noonan G, Gaile S, et al. Effect of montelukast or salmeterol added to inhaled fluticasone on exercise-induced bronchoconstriction in children. Ann Allergy Asthma Immunol 2010;104(6):511–7. https://www.ncbi.nlm.nih.gov/pubmed/20568384
Global Initiative for Asthma (GINA)Global strategy for asthma management and prevention: main report. Wisconsin: GINA; 2019. www.ginasthma.org
Jartti T. Inhaled corticosteroids or montelukast as the preferred primary long-term treatment for pediatric asthma? Eur J Pediatr 2008;167(7):731–6. https://www.ncbi.nlm.nih.gov/pubmed/18214538
Kaiser SV, Huynh T, Bacharier LB, Rosenthal JL, Bakel LA, Parkin PC, et al. Preventing exacerbations in preschoolers with recurrent wheeze: a meta-analysis. Pediatrics 2016;137(6). https://www.ncbi.nlm.nih.gov/pubmed/27230765
Maspero J, Guerra F, Cuevas F, Gutierrez JP, Soto-Ramos M, Anderton S, et al. Efficacy and tolerability of salmeterol/fluticasone propionate versus montelukast in childhood asthma: a prospective, randomized, double-blind, double-dummy, parallel-group study. Clin Ther 2008;30(8):1492–504. https://www.ncbi.nlm.nih.gov/pubmed/18803991
Nagao M, Ikeda M, Fukuda N, Habukawa C, Kitamura T, Katsunuma T, et al. Early control treatment with montelukast in preschool children with asthma: a randomized controlled trial. Allergol Int 2018;67(1):72–8. https://www.ncbi.nlm.nih.gov/pubmed/28526210
National Asthma Council AustraliaAustralian Asthma Handbook, v2.1. Melbourne: National Asthma Council Australia; 2020. https://www.asthmahandbook.org.au/
Szefler SJ, Carlsson LG, Uryniak T, Baker JW. Budesonide inhalation suspension versus montelukast in children aged 2 to 4 years with mild persistent asthma. J Allergy Clin Immunol Pract 2013;1(1):58–64. https://www.ncbi.nlm.nih.gov/pubmed/24229823
Valovirta E, Boza ML, Robertson CF, Verbruggen N, Smugar SS, Nelsen LM, et al. Intermittent or daily montelukast versus placebo for episodic asthma in children. Ann Allergy Asthma Immunol 2011;106(6):518–26. https://www.ncbi.nlm.nih.gov/pubmed/21624752